Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01245335
Recruitment Status : Completed
First Posted : November 22, 2010
Last Update Posted : December 15, 2015
Information provided by (Responsible Party):
Harvest Technologies

Brief Summary:
Critical Limb Ischemia prevents the legs and feet from receiving oxygen and nutrients needed for proper function. This severe lack of blood flow can lead to painful legs while walking or at rest and can result in foot sores, ulcers, gangrene, and even amputation. The purpose of this study is to determine if injections of concentrated bone marrow into damaged tissues will result in improved blood flow. If successful, this treatment could improve blood flow to the lower limb, reduce pain, and reduce the frequency of limb amputations.

Condition or disease Intervention/treatment Phase
Critical Limb Ischemia Device: BMAC injection Device: Placebo injection Phase 3

Detailed Description:
Bone marrow aspirate is collected and processed by centrifugation to remove red blood cells. The resulting concentrate of cells is injected into ischemic tissues of the lower limb. The purpose of this study is to determine if injections of concentrated bone marrow nucleated cells into ischemic tissues will result in vasculogenesis.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease
Study Start Date : May 2011
Actual Primary Completion Date : August 2015
Actual Study Completion Date : November 2015

Arm Intervention/treatment
Active Comparator: BMAC Treatment
Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
Device: BMAC injection
Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
Placebo Comparator: Placebo Injection
Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
Device: Placebo injection
Injection of placebo into ischemic tissue of the lower extremity

Primary Outcome Measures :
  1. Amputation Free Survival [ Time Frame: Six Months ]
    Survival without a major (above the ankle) amputation

Secondary Outcome Measures :
  1. Change In Rutherford Classification [ Time Frame: Six Months ]
    Change in the subjects clinical status as measured by Rutherford Classification

  2. Change in Pain [ Time Frame: Six Months ]
    Change in Subjects perception of pain as measured on a 100 mm visual analog scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has Peripheral Arterial Occlusive Disease (PAOD) with clinical Rutherford Category 5 disease, as defined in the reporting standards adopted by the Society of Vascular Surgeons(table 1); Minor Tissue loss-focal gangrene with diffuse pedal ischemia
  • Patient meets at least one of the following diagnostic criteria in the study limb:

    • Ankle artery occlusion pressure absolute ≤60 mmHg or ABI ≤0.6
    • Toe artery occlusive pressure < 50mm Hg or TBI ≤0.6
  • There is no reasonable open surgical or endovascular revascularization option as determined by the treating vascular specialist. Factors that may contribute to the determination of inoperability may include:

    • Anatomical considerations
  • No outflow targets
  • No appropriate conduit (i.e. vein for bypass)
  • Long segment occlusions or calcified lesions that predict poor outcome with endovascular approaches.

    • High risk medical conditions i.e. Unstable cardiac disease.
    • History of prior failed revascularization attempts
  • The Patient's case was reviewed at the treating institution's Multidisciplinary Vascular Conference where the patient's status as a poor candidate for conventional therapies was confirmed.
  • Age ≥18 years and ability to understand the planned treatment
  • Subject has read and signed the IRB approved Informed Consent form
  • Patients for whom the following medication(s) is prescribed must have a one month stable baseline therapy prior to enrollment: Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or blood pressure medication. If any of these medications are not prescribed notation of the reason for omission is to be provided.
  • Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 2.5 mg / dL, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery.

Exclusion Criteria:

  • Life expectancy <6 months due to concomitant illnesses
  • History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation
  • Terminal renal failure with existing dependence on dialysis or serum creatinine >2.5 mg/dL
  • Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free.
  • Poorly controlled diabetes mellitus (HgbA1C>10%)
  • Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5
  • Life-threatening complications of the ischemia necessitating immediate amputation
  • Uncorrected occlusion of the common or external iliac artery on index side
  • Absence of any pulsatile Doppler flow below the ankle.
  • Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6).
  • Ulceration with exposed bone proximal to the distal metatarsal heads (ie. heel or mid foot)
  • Active clinical infection or infection being treated by antibiotics within one week of enrollment
  • Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day).
  • Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method.
  • Underwent a major open cardiovascular surgical procedure (carotid endarterectomy, arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or a myocardial infarction within the 3 months prior to randomization
  • Underwent a successful or partially successful endovascular intervention for peripheral arterial occlusive disease. (ie. Aorta, iliac, femoral, popliteal, or tibial artery angioplasty, stenting, or atherectomy) within the prior 3 months.
  • Endovascular coronary intervention (ie. Angioplasty, atherectomy, stenting) within 1 month prior to randomization.
  • Underwent a failed attempt for endovascular revascularization during the prior 1 month. For the purpose of this exclusion criteria an endovascular procedure is considered a failure if:

    1. The procedure is diagnostic only with no intervention performed, (for example in the case where wire crossing can not be obtained).
    2. The treated artery recoils, thromboses, or dissects resulting in occlusion of the treated arterial segment, documented by intraoperative imaging. Note that endovascular procedures with suboptimal results but not meeting criteria 1 or 2 above may qualify for inclusion after 3 months as in #16 above.
  • Cerebrovascular accident within 6 months prior to randomization.
  • Treatment with topical growth factors or hyperbaric oxygen (HBO) within 30 days, or systemic growth factor treatment within 6 months of enrollment.
  • Known hypersensitivity to heparin; or history of heparin-induced thrombocytopenia (HIT).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01245335

  Hide Study Locations
United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35294-0012
United States, Arkansas
Medical Center of South Arkansas
El Dorado, Arkansas, United States, 71730
United States, California
USC Keck School of Medicine
Los Angeles, California, United States, 90033
United States, Florida
Florida Hospital - Vascular Institute of Central Florida
Orlando, Florida, United States, 32804
Coastal Vascular & Interventional
Pensacola, Florida, United States, 32503
USF / Tampa General
Tampa, Florida, United States, 33606
United States, Illinois
University of Illinois-Chicago
Chicago, Illinois, United States, 60612
Cadence Health, Central DuPage Hospital
Winfield, Illinois, United States, 60190
United States, Louisiana
Ochsner Clinic
New Orleans, Louisiana, United States, 70121
United States, Maine
Maine Medical Ctr
Portland, Maine, United States, 04102
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
Beth Israel Deaconess
Boston, Massachusetts, United States, 02215
United States, Missouri
Kansas City Vascular
Kansas City, Missouri, United States, 64116
Mercy Hospital
St. Louis, Missouri, United States, 63141
United States, New Hampshire
Dartmouth Hitchcock Medical Ctr
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States, 08103
Holy Name Medical Center
Teaneck, New Jersey, United States, 07666
United States, New York
North Shore-Long Island Jewish
Lake Success, New York, United States, 11042
St. Luke's Roosevelt
New York, New York, United States, 10025
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Regional Infectious Disease and Infusion Ctr
Lima, Ohio, United States, 45801
United States, Oklahoma
University of Oklahoma
Tulsa, Oklahoma, United States, 74135
United States, Oregon
Oregon Health Science University
Portland, Oregon, United States, 97239
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
United States, South Carolina
Roper St Francis Medical Center
Charleston, South Carolina, United States, 29401
Greenville Health System
Greenville, South Carolina, United States, 29615
United States, Tennessee
University of Tennessee
Knoxville, Tennessee, United States, 37920
United States, Texas
Baylor Medical Ctr
Dallas, Texas, United States, 75226
University of Texas - Houston Medical School
Houston, Texas, United States, 77030
United States, Washington
Peace Health Southwest Medical Center
Vancouver, Washington, United States, 98682
United States, West Virginia
Charleston Area Medical Center Institute
Charleston, West Virginia, United States, 25304
Sponsors and Collaborators
Harvest Technologies
Principal Investigator: Mark Iafrati, MD Tufts Medical Ctr

Responsible Party: Harvest Technologies Identifier: NCT01245335     History of Changes
Other Study ID Numbers: CLI-2011-1
First Posted: November 22, 2010    Key Record Dates
Last Update Posted: December 15, 2015
Last Verified: December 2015

Keywords provided by Harvest Technologies:
Critical Limb Ischemia
Peripheral Arterial Disease
Stem Cells
Limb amputation
Leg ulcers

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases